Therapeutic progress. I: Current treatment of rheumatoid arthritis.
Over recent years the pharmacological treatment strategy for rheumatoid arthritis (RA) has changed. An early, aggressive approach has been adopted with a view to maintaining functional capacity. The changing role of nonsteroidal anti-inflammatory agents is discussed in the light of the potential toxicity of this class of drugs. The current use of second-line agents is dealt with in depth and includes guidelines to patient monitoring. Particular attention has been paid to the growing use of cyclosporin A in the treatment of RA as this drug represents the newest, most potent, nonexperimental form of treatment. The questions of when to introduce second-line agents, who should receive treatment and how many drugs should be prescribed are all addressed in this review. The relative efficacy and toxicity of these agents is discussed and a treatment protocol is proposed.
Gittoes
N J
NJ
Department of Medicine, Queen Elizabeth Hospital, Birmingham, U.K.
D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D006801:Humans